The Global Health Innovative Technology Foundation (GHIT Fund) and the European and Developing Country Clinical Trials Partnership (EDCTP) have announced that they will make a new joint investment of approximately 980 million yen in the Praziquantel Pediatric Consortium.
Astellas Pharma Inc. and others are participating in the Praziquantel Pediatric Consortium. With this fund, an ADOPT program will be implemented in a country where schistosomiasis is widespread, considering various aspects such as technology transfer, manufacturing, logistics, and social mobilization of pediatric praziquantel / PZQ tablets developed for preschool children with schistosomiasis. ..
Click here for details